» Articles » PMID: 7831284

Sequence and Structure of VH Domain from Naturally Occurring Camel Heavy Chain Immunoglobulins Lacking Light Chains

Overview
Journal Protein Eng
Date 1994 Sep 1
PMID 7831284
Citations 159
Authors
Affiliations
Soon will be listed here.
Abstract

We cloned 17 different PCR fragments encoding VH genes of camel (Camelus dromedarius). These clones were derived from the camel heavy chain immunoglobulins lacking the light chain counterpart of normal immunoglobulins. Insight into the camel VH sequences and structure may help the development of single domain antibodies. The most remarkable difference in the camel VH, consistent with the absence of the VL interaction, is the substitution of the conserved Leu45 by an Arg or Cys. Another noteworthy substitution is the Leu11 to Ser. This amino acid normally interacts with the CH1 domain, a domain missing in the camel heavy chain immunoglobulins. The nature of these substitutions agrees with the increased solubility behavior of an isolated camel VH domain. The VH domains of the camels are also characterized by a long CDR3, possibly compensating for the absence of the VL contacts with the antigen. The CDR3 lacks the salt bridge between Arg94 and Asp101. However, the frequent occurrence of additional Cys residues in both the CDR1 and CDR3 might lead to the formation of a second internal disulfide bridge, thereby stabilizing the CDR structure as in the DAW antibody. Within CDRs of the camel VH domains we observe a broad size distribution and a different amino acid pattern compared with the mouse or human VH. Therefore the camel hypervariable regions might adopt structures which differ substantially from the known canonical structures, thereby increasing the repertoire of the camel antigen binding sites within a VH.

Citing Articles

Presence of EGF ligand restricts the binding ability of EgB4 nanobody to EGFR extracellular domain.

Truong D, Chwastyk M, Viet T, Phung V, Nguyen M Sci Rep. 2025; 15(1):2420.

PMID: 39827297 PMC: 11742981. DOI: 10.1038/s41598-025-86646-z.


Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery.

Vuong C, Reynolds K, Rivera G, Zeng B, Karimpourkalou Z, Norng M MAbs. 2024; 16(1):2435476.

PMID: 39607037 PMC: 11610561. DOI: 10.1080/19420862.2024.2435476.


On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality.

Fernandez-Quintero M, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F Protein Sci. 2024; 33(11):e5176.

PMID: 39422475 PMC: 11487682. DOI: 10.1002/pro.5176.


Single domain antibody: Development and application in biotechnology and biopharma.

Yu T, Zheng F, He W, Muyldermans S, Wen Y Immunol Rev. 2024; 328(1):98-112.

PMID: 39166870 PMC: 11659936. DOI: 10.1111/imr.13381.


TEMPRO: nanobody melting temperature estimation model using protein embeddings.

Alvarez J, Dean S Sci Rep. 2024; 14(1):19074.

PMID: 39154093 PMC: 11330463. DOI: 10.1038/s41598-024-70101-6.